免疫抑制剂PD-1/PD-L1治疗卵巢癌的研究进展

doi:10.11904/j.issn.1002-3070.2020.03.015

Abstract

Abstract: Ovarian cancer is the most deadly gynecological malignancy in women from European and the United States.Its pathogenesis is complex pathogenesis and easy to recurrence.The prognosis is still poor after active treatment.At present,immunotherapy has become a new type of anti-tumor therapy after traditional therapies,in which programmed cell death receptor-1(PD-1)/programmed cell death ligand-1(PD-L1)inhibitors have shown remarkable efficacy in the treatment of various malignant tumors including melanoma and non-small cell lung cancer,and other malignant tumors.However,their effects on the clinical treatment of ovarian cancer need to be studied.This article summarizes the progress of PD-1/PD-L1 immunosuppressive agents in ovarian cancer and the treatment of side effects,and explores the feasibility of applying immunosuppressive agents to ovarian cancer,which brings hope for the treatment of ovarian cancer.

Key words: Ovarian cancer, Programmed cell death-1/programmed cell death ligand-1 inhibitors, Immunotherapy, Immunity inhibitor

CLC Number:

R737.31

HOU Jianying,ZHU Wei. Research progress of immunosuppressive PD-1/PD-L1 in treatment of ovarian cancer[J]. Journal of Practical Oncology, 2020, 34(3): 266-270.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2020.03.015

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2020/V34/I3/266

References

1 Siegel RL,Miller KD,Jemal A.Cancer statistics,2017[J].CA Cancer J Clin,2017,67(1):7-30.
2 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
3 Cortez AJ,Tudrej P,Kujawa KA,et al.Advances in ovarian cancer therapy[J].Cancer Chemother Pharmacol,2018,81(1):17-38.
4 Reid BM,Permuth JB,Sellers TA.Epidemiology of ovarian cancer:a review[J].Cancer Biol Med,2017,14(1):9-32.
5 Bozas G,Terpos E,Gika D,et al.Prechemotherapy serum levels of CD105,transforming growth factor beta2,and scular endothelial growth factor are associated with prognosis in patients with dvanced epithelial ovarian cancer treated with cytoreductive surgery andplatinum-based emotherapy[J].Int J Gynecol Cancer,2010,20(2):248-254.
6 Kleffel S,Posch C,Barthel SR,et al.Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth[J].Cell,2015,162(6):1242-1256.
7 张智,张一琼.Foxp3+Tregs及PD1在上皮性卵巢癌组织中的表达及其临床病理意义[J].南昌大学学报(医学版),2018,58(5):54-58.
8 Tan D,Sheng L,Yi QH.Correlation of PD-1/PD-L1 polymorphisms and expressions with clinicopathologic features and prognosis of ovarian cancer[J].Cancer Biomark,2018,21(2):287-297.
9 韩滕,唐丽萍.PD-L1的表达与妇科恶性肿瘤预后关系的研究进展[J].实用肿瘤学杂志,2018,32(5):468-470.
10 Zou W,Chen L.Inhibitory B7 family molecules in the tumour microenvironment[J].Nat Rev Immunol,2008,8(6):467-477.
11 Hamanishi J,Mandai M,Iwasaki M,et al.Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancer[J].Proc Natl Acad Sci U S A,2007,104(9):3360-3365.
12 Abiko K,Mandai M,Hamanishi J,et al.PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction[J].Clin Cancer Res,2013,19(6):1363-1374.
13 Darb-Esfahani S,Kunze CA,Kulbe H,et al.Prognostic impact of programmed cell death-1(PD-1)and PD-ligand 1(PD-L1)expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma[J].Oncotarget,2016,7(2):1486-1499.
14 Shaheen S,Mirshahidi H,Nagaraj G,et al.Conservative management of nivolumab-induced pericardial effusion:a case report and review of literature[J].Exp Hematol Oncol,2018,7(11):1-5.
15 Hamanishi J,Mandai M,Ikeda T,et al.Safety and antitumor activity of anti-PD-1 antibody,Nivolumab,in patients with platinum-resistant ovarian cancer[J].J Clin Oncol,2015,33(34):4015-4022.
16 Zorn KK,Bonome T,Gangi L,et al.Gene expression profiles of serous,endometrioid,and clear cell subtypes of ovarian and endometrial cancer[J].Clin Cancer Res,2005,11(18):6422-6430.
17 Inayama Y,Hamanishi J,Matsumura N,et al.Antitumor effect of Nivolumab on subsequent chemotherapy for platinum-resistant ovarian cancer oncologist[J].Oncologist,2018,23(11):1382-1384.
18 Normann MC,Türzer M,Diep LM,et al.Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer[J].J Gynecol Oncol,2019,30(4):e56.
19 Boyiadzis MM,Kirkwood JM,Marshall JL,et al.Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease[J].J Immunother Cancer,2018,6(35):1-7.
20 Varga A,Piha-Paul S,Ott PA,et al.Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer:analysis of KEYNOTE-028[J].Gynecol Oncol,2019,152(2):243-250.
21 Matulonis UA,Shapira-Frommer R,Santin AD,et al.Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer:results from the phase 2 KEYNOTE-100 study[J].Ann Oncol,2019,30(7):1080-1087.
22 Herbst RS,Soria JC,Kowanetz M,et al.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J].Nature,2014,515(7528):563-567.
23 Infante JR,Braiteh F,Emens LA,et al.Safety,clinical activity and biomarkers of atezolizumab(atezo)in advanced ovarian cancer(OC)[J].Ann Oncol,2016,27(6):296-312.
24 Liu JF,Gordon M,Veneris J,et al.Safety,clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers[J].Gynecol Oncol,2019,154(2):314-322.
25 Heery CR,Sullivan Coyne GH,Madan RA,et al.Phase I open-label,multiple ascending dose trial of MSB0010718C,an anti-PD-L1 monoclonal antibody,in advanced solid malignancies[J].J Clin Oncol,2014,32(15):3064.
26 Boyerinas B,Jochems C,Fantini M,et al.Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab(MSB0010718C)on human tumor cells[J].Cancer Immunol Res,2015,3(10):1148-1157.
27 Disis ML,Taylor MH,Kelly K,et al.Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer:phase 1b results from the JAVELIN solid tumor trial[J].JAMA Oncol,2019,5(3):393-401.
28 Zhang L,Chen Y,Li F,et al.Atezolizumab and bevacizumab Attenuate cisplatin resistant ovarian cancer cells progression synergistically via suppressing epithelial-mesenchymal transition[J].Front Immunol,2019,10:867.
29 Liu JF,Herold C,Gray KP,et al.Assessment of combined Nivolumab and bevacizumab in relapsed ovarian cancer:A phase 2 clinical trial[J].JAMA Oncol,2019[Epub ahead of print].
30 Konstantinopoulos PA,Waggoner S,Vidal GA,et al.Single-arm phases 1 and 2 trial of Niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma[J].JAMA Oncol,2019[Epub ahead of print].
31 Drew Y,De Jonge M,Hong SH,et al.An open-label,phase II basket study of olaparib and durvalumab(MEDIOLA):Results in germline BRCA-mutated(gBRCAm)platinum sensitive relapsed(PSR)ovarian cancer(OC)[J].Gynecol Oncol,2018,149:246-247.
32 Lee JM,Cimino-Mathews A,Peer CJ,et al.Safety and clinical activity of the programmed death-ligand 1 inhibitor Durvalumab in combination with poly(ADP-ribose)polymerase inhibitor Olaparib or vascular endothelial growth factor receptor 1-3 inhibitor Cediranib in Women′s cancers:a dose-escalation,phase I study[J].J Clin Oncol,2017,35(19):2193-2202.
33 Topalian SL,Sznol M,McDermott DF,et al.Survival,durable tumor remission,and long-term safety in patients with advanced melanoma receiving nivolumab[J].J Clin Oncol,2014,32(10):1020-1030.

[1]	LIU Chao, ZHENG Tongsen. Summary and reflection on the medical work of oncology during the outbreak of corona virus disease 2019 [J]. Journal of Practical Oncology, 2020, 34(2): 100-102.
[2]	LIANG Yongqin, ZHAO Hongwei. Application progress of antiangiogenic drugs in platinum-resistant ovarian cancer [J]. Journal of Practical Oncology, 2020, 34(1): 60-63.
[3]	HUANG Li, LONG Youmei, FU Yixia, XIA Liangbin. Effect of pterostilbene on apoptosis and glycolysis of ovarian cancer SKOV3 cells and its mechanism [J]. Journal of Practical Oncology, 2019, 33(6): 502-507.
[4]	DENG Mingxin, ZHANG Ying. Research progress of circRNAs and ovarian cancer [J]. Journal of Practical Oncology, 2019, 33(6): 549-552.
[5]	ZHANG Huiting, LOU Ge. Research progress in 3D cell culture model of ovarian cancer tumor microenvironment [J]. Journal of Practical Oncology, 2019, 33(6): 557-560.
[6]	CAO Difei, HUANG Guoqing, XUE Jiaying, WU Qiong, WANG Lei, LI Yao. The role of CA153 in breast cancer immunotherapy [J]. Journal of Practical Oncology, 2019, 33(6): 566-569.
[7]	SONG Ling, FU Qiong. Astragalin inhibits hypoxia-induced proliferation and invasion of ovarian cancer cells by up-regulating PHD2 [J]. Journal of Practical Oncology, 2019, 33(5): 407-414.
[8]	ZHANG Beilei, LI Yi, WU Tao, JIANG Feng, ZHAO Hongxi, LI Yanhong. Mechanism study of sanguinarine inhibiting tumor growth of ovarian cancer by apoptosis induction [J]. Journal of Practical Oncology, 2019, 33(4): 305-309.
[9]	YAO Yang, ZHANG Yanqiao. Mechanism and recent progress of gastric cancer in immunological checkpoint inhibitors [J]. Journal of Practical Oncology, 2019, 33(4): 371-375.
[10]	LV Bowen, QIAN Jun, WANG Jie, QIAN Jingrong, LU Yingying, SU Liju, YANG Tongshu, LI Wenhui. Expression of MiR-455-5p in epithelial ovarian cancer and its target gene function [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 115-121.
[11]	SONG Ling, FU Qiong. Study of the effect of astragalin on proliferation of ovarian cancer cells by inhibiting the glycolytic pathway induced Via HIF-1α [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 503-509.
[12]	JIANG Liangliang, WANG Jing. Progress in diagnosis and treatment of distant metastasis of epithelial ovarian cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 480-482.
[13]	LIANG Guanying,CHI Qiujun,LI Xiaomei. Effect and mechanism of Vorinostat on the proliferation and apoptosis of ovarian cancer SKOV3 cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 298-302.
[14]	SUN Zugang,WANG Zhe,CHEN Huaian,LIU Shuo,MIAO Wenlong. Progress in common chronic inflammatory factors inducing bladder cancer and its immunotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 357-361.
[15]	LI Wenhui, LV Bowen, QIAN Jun, SU Liju, YANG Tongshu, QIAN Jingrong, WANG Jie. Effect of microRNA-150 on proliferation,apoptosis,invasion and metastasis of epithelial ovarian cancer cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 208-213.

Research progress of immunosuppressive PD-1/PD-L1 in treatment of ovarian cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments